- PII
- S30345057S2686738925040169-1
- DOI
- 10.7868/S3034505725040169
- Publication type
- Article
- Status
- Published
- Authors
- Volume/ Edition
- Volume 523 / Issue number 1
- Pages
- 474-478
- Abstract
- A comparative study of three drugs (KRRKPGP peptide, warfarin and acetylsalicylic acid) with an anticoagulant effect in the body was conducted. The drugs were administered orally in effective doses (peptide and warfarin‑100 mcg/kg, acetylsalicylic acid –1 mg/kg) for 7 days to laboratory rats with metabolic syndrome induced by a high-calorie diet (HCD). After 20 hours after the last administration of the drugs, a decrease in the concentration of total cholesterol, low-density lipoprotein cholesterol, triglycerides and an increase in the concentration of high-density lipoprotein cholesterol and a slowdown in the growth of body weight in rats were detected, which persisted for 7 days after stopping their administration. The greatest hypolipidemic effect was caused by the KRRKPGP peptide.
- Keywords
- ацетилсалициловая кислота варфарин липидный профиль масса тела метаболический синдром регуляторный пептид
- Date of publication
- 15.06.2025
- Year of publication
- 2025
- Number of purchasers
- 0
- Views
- 47
References
- 1. Li X., Weber N.C., Cohn D.M., et al., Effects of hyperglycemia and diabetes mellitus on coagulation and hemostasis // J Clin Med. 2021. V. 10. P. 2419.
- 2. Bovolini A., Garcia J., Andrade M.A., Duarte J.A. Metabolic syndrome pathophysiology and predisposing factors // Int J Sports Med. 2021. V. 42. № 3. P. 199–214.
- 3. Hayden M.R. Overview and new insights into the metabolic syndrome: risk factors and emerging variables in the development of type 2 diabetes and cerebrovascular disease // Medicina. 2023. V. 59. № 3. P. 561.
- 4. Myasoedov N.F., Lyapina L.A., Andreeva L.A., et al. The modern view on the role of glyprolines by metabolic syndrome // Med Res Rev. 2021. V. 41. № 5. P. 2823–2840.
- 5. Czuprynska J., Patel J.P., Arya R. Current challenges and future prospects in oral anticoagulant therapy // Br J Haematol. 2017. V. 178. № 6. P. 838–851.
- 6. Rood K.M., Patel N., DeVengencie I.M., et al. Aspirin modulates production of pro-inflammatory and pro-resolving mediators in endothelial cells // PLoS One. 2023. V. 18. 4. P. e0283163.
- 7. Yamagishi S.I. Concern about clinical efficacy and safety of warfarin in diabetic patients with atrial fibrillation // Cardiovasc Diabetol. 2019. V. 18. P. 12.
- 8. Roy S., Bhowmik D.R., Begum R., et al. Aspirin attenuates the expression of adhesion molecules, risk of obesity, and adipose tissue inflammation in high-fat diet-induced obese mice // Prostaglandins and Other Lipid Mediat. 2022. V. 162. P. 106664.
- 9. Angiolillo D.J., Bhatt D.L., Lanza F., et al. Pharmacokinetic/pharmacodynamics assessment of a novel, pharmaceutical lipid-aspirin complex: results of a randomized, crossover, bioequivalence study // J Thromb Thrombolysis. 2019. V. 48. № 4. P. 554–562.
- 10. Кытикова О.Ю., Антонюк М.В., Кантур Т.А. и др. Распространенность и биомаркеры метаболического синдрома // Ожирение и метаболизм. 2021. Т. 18. № 3. С. 302–312.
- 11. Справочник Видаль. Лекарственные препараты в России. М.: Видаль Рус, 2023.
- 12. Мясоедов Н.Ф., Ляпина Л.А., Оберган Т.Ю. и др. Влияние пептидов KKRRPGP (Lys-Lys-Arg-Arg-Pro-Gly-Pro) и KRRKPGP (Lys-Arg-Arg-Lys-Pro-Gly-Pro) на параметры гемостаза, липидный профиль, уровень глюкозы крови и изменение массы тела крыс на фоне метаболического синдрома и дисфункции эндотелия // Вестн. Моск. ун-та. Сер. 16. Биология. 2021. Т. 76. № 1. С. 10–17.
- 13. Duparc C., Andre C., Menard J. et al. l-Lysine acts as a serotonin type 4 receptor antagonist to counteract in vitro and in vivo the stimulatory effect of serotonergic agents on aldosterone secretion in man // Horm Metab Res. 2017. № 4. P. 269–275.
- 14. Shabalina A.A., Lyapina L.A., Rochev D.L., et al. In vitro lipid-lowering and fibrinolytic effects of regulatory leucine-containing glyprolines in human blood // Biol Bull. 2015. V. 42. № 1. P. 74–77.
- 15. Григорьева М.Е., Ляпина Л.А., Шубина Т.А. и др. Защитные эффекты Pro-Gly-Pro-Arg в условиях повышенной свертываемости крови при экспериментальной гипергликемии // Тромбоз, гемостаз и реология. 2011. № 3. С. 41–46.
- 16. Makki N.F. Effect of warfarin on cholesterol, LDL, HDL and TG levels in coronary artery patients with type // Biomed Pharmacother. 2016. V. 83. P. 14–21.
- 17. Michlacova J., Bulikova A., Zavr'elova J., et al. The current role of warfarin // Vnitr Lek. 2018. V. 63. P. 957–966.
